Industry Connections
This content and the opinions expressed herein are those of the supporter or industry event provider and not those of the San Antonio Breast Cancer Symposium (SABCS®).
The San Antonio Breast Cancer Symposium (SABCS®) has no editorial oversight in the creation of content provided or supported by industry.
Provided Content
-
Clinical applications of Cerianna (FES) PET: A case-based perspective
At 2025 SABCS®, join Drs. Joanne Mortimer and Susan Cha for a case-based discussion on the clinical applications of Cerianna in estrogen receptor-positive (ER+) recurrent and metastatic breast cancer patients.
-
VISIT GENENTECH BOOTH #143 for the INAVO120 PFS and OS Data
INDUSTRY PROVIDED CONTENT Visit Genentech Booth #143 for the INAVO120 PFS and OS Data Explore the primary and exploratory PFS analyses, and the final OS analysis for the Itovebi® (inavolisib) […]
Supported Content
-
First-line ADC Data Provides Hope for Improved Patient Outcomes in mTNBC
Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype and is more likely to recur and to metastasize than other types of breast cancer. Five-year survival for patients with metastatic TNBC is estimated to be 15%, which emphasizes the unmet clinical need for novel first-line therapies in this space. Clinical trial data presented at both the European Society for Medical Oncology Congress 2025 and the 2025 San Antonio Breast Cancer Symposium® on antibody–drug conjugates in the first-line setting have provided reasons for optimism, however.
-
Putting Recent Data to Work in the Real World for HER2+ Metastatic Breast Cancer
Moving away from the CLEOPATRA regimen for first-line treatment of all patients with HER2+ metastatic breast cancer has taken over a decade, but recent clinical trials in this space highlight new potential approaches to induction and maintenance therapy for select patients. Additionally, real-world treatment may soon be tailored by hormone receptor status and presence of brain metastases. In the associated Q&A, Drs. Reva Basho and VK Gadi discuss the nuances of how the AFT-38 PATINA, DESTINY-Breast09, and HER2CLIMB-05 trials could fit into the overall landscape for patients with HER2+ metastatic breast cancer.
-
Appropriate Monitoring and Multidisciplinary Coordination Can Help Avoid Serious Hyperglycemia for Patients with PI3K/AKT Alterations and HR+/HER2- Breast Cancer
Many patients with HR+/HER2- breast cancer develop resistance to endocrine therapy, making management of metastatic disease complicated. Alterations in the PI3K/AKT/mTOR pathway are often the cause of this resistance, making testing for related alterations vital for metastatic therapeutic selection. Once a patient is a candidate for PI3K or AKT inhibition, breast cancer care providers must understand how to avoid and manage hyperglycemia, as this is a known adverse event from these agents.
-
Experts Shine Light on ADCs in First-line Metastatic TNBC: Understanding Nuanced Differences in Trial Designs & Prophylactic Approaches to Adverse Events
Metastatic triple-negative breast cancer (mTNBC) is a highly symptomatic disease that is associated with poor survival outcomes so new approaches to first-line therapies have been desperately needed. Although both antibody–drug conjugates that made waves at the podiums of large oncology meetings in 2025 including the San Antonio Breast Cancer Symposium, reported positive data based on similar clinical trials’ populations, it is important to dig a little deeper to understand the nuances associated with each trial and each agent.
-
Advancing Therapeutic Options for Patients in TNBC
Immunotherapy, PARP inhibitors, and antibody-drug conjugates have revolutionized the therapeutic landscape for triple-negative breast cancer (TNBC). With new compounds and combinations under investigation, lessons learned in metastatic TNBC are becoming equally valuable in early-stage disease, as well as in other subsets of breast cancer. Learn from Sonya Reid, MD, MPH, and Manali Bhave, MD, about the current landscape and how it may evolve. Kayla Freeman, DNP, reviews best practices for prophylactic and reactive management of common side effects with antibody-drug conjugates of interest.